Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance

Current Opinion in Investigational Drugs

Volumn 6, Issue 10, 2005, Pages 988-993

  Haluzik, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adiponectin; Adipose tissue; Atherosclerosis; Diabetes; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; GLIMEPIRIDE; METFORMIN; OSMOTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

DRUG EFFICACY; GENE EXPRESSION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW;

DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INSULIN RESISTANCE; OBESITY; RECOMBINANT PROTEINS;

EID: 27544513825     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Reaven G: Metabolic syndrome: Pathophysiology and implications for management of cardiovascular disease. Circulation (2002) 106(3):286-288.
2. Reaven GM: Syndrome X. Blood Press Suppl (1992) 4:13-16.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 339(4):229-234.
4. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation (1996) 93(10):1809-1817.
5. Brichard SM, Delporte ML, Lambert M: Adipocytokines in anorexia nervosa: A review focusing on leptin and adiponectin. Horm Metab Res (2003) 35(6):337-342.
6. Campfield LA, Smith FJ, Burn P: The OB protein (leptin) pathway - a link between adipose tissue mass and central neural networks. Horm Metab Res (1996) 28(12):619-632.
7. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science (1993) 259(5091):87-91.
8. Hotamisligil GS, A?mer P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest (1995) 95(5):2409-2415.
9. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372(6505):425-432.
10. Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol (2002) 13(1):51-59.
11. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 270(45):26746-26749.
12. Hu E, Liang P, Splegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem (1996) 271(18):10697-10703.
13. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun (1996) 221(2):286-289.
14. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) (1996) 120(4):803-812.
15. Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol (2002) 440(2-3):213-221.
16. Trujillo ME, Scherer PE: Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med (2005): 257(2):167-175.
17. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE: Structure-function studies of the adipocyte-secreted hormone ACRP30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem (2003) 278(11):9073-9085.
18. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K et al: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 423(6941):762-769.
19. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF: T-cadherin is a receptor for hexameric and high-molecular-weight forms of ACRP30/adiponectin. Proc Natl Acad Sci USA (2004) 101(28):10308-10313.
20. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 8(11):1288-1295.
21. Viengchareun S, Zennaro MC, Pascual-Le Tallec L, Lombes M: Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett (2002) 532(3):345-350.
22. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2002) 290(3):1084-1089.
23. Makimura H, Mizuno TM, Bergen H, Mobbs CV: Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab (2002) 283(6):E1266-E1271.
24. Puerta M, Abelenda M, Rocha M, Trayhum P: Effect of acute cold exposure on the expression of the adiponectin, resistin and leptin genes in rat white and brown adipose tissues. Horm Metab Res (2002) 34(11-12):629-634.
25. Schaffler A, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J, Zietz B: Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes (2004) 112(7):383-389.
26. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 7(8):941-946.
27. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 257(1):79-83.
28. Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B, Dietz KR, Le Roith D, Reitman ML: Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology (2004) 145(7):3258-3264.
29. Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, Pajvani UB, Scherer PE, LeRoith D: Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia (2004) 47(12):2215-2225.
30. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM et al: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2004) 279(13):12152-12162.
31. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes (2001) 50(5):1126-1133.
32. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R et al: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med (2002) 8(7):731-737.
33. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W et al: Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem (2002) 277(29):25863-25866.
34. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N et al: Adiponectin reduces atherosclerosis in apolipoproteln E-deficient mice. Circulation (2002) 106(22):2767-2770.
35. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K et al: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation (2001) 103(8):1057-1063.
36. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun (2004) 314(2):415-419.
37. Shimada K, Miyazaki T, Daida H: Adiponectin and atherosclerotic disease. Clin Chim Acta (2004) 344(1-2):1-12.
38. Matsuzawa Y: Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl (2005) 6(2):7-14.
39. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab (2001) 86(8):3815-3819.
40. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab (2001) 86(5):1930-1935.
41. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol (2000) 20(6):1595-1599.
42. Pannacciulli N, Vettor R, Milan G, Granzotto M, Catucci A, Federspil G, De Giacomo P, Giorgino R, De Pergola G: Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab (2003) 88(4):1748-1752.
43. Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM: Pre- and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion: In vitro and in vivo studies. Biochem J (2002) 367(3):677-685.
44. Housova J, Anderlova K, Krizova J, Haluzikova D, Kremen J, Kumstyrova T, Papezova H, Haluzik M: Serum adiponectin and resistin concentrations in patients with restrictive and binge/purge form of anorexia nervosa and bulimia nervosa. J Clin Endocrinol Metab (2005) 90(3):1366-1370.
45. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L et al: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA (2000) 97(26):14478-14483.
46. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, Kadowaki H et al: Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes (2002) 51(2):536-540.
47. Zacharova J, Chiasson JL, Laakso M: The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: The STOP-NIDDM trial. Diabetes (2005) 54(3):893-899.
48. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA (2001) 98(4):2005-2010.
49. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein ACRP30 enhances hepatic insulin action. Nat Med (2001) 7(8):947-953.
50. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: Endogenous glucose production is inhibited by the adipose-derived protein ACRP30. J Clin Invest (2001) 108(12):1875-1881.
51. Satoh H, Nguyen MT, Trujillo M, Imamura T, Usui I, Scherer PE, Olefsky JM: Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes (2005) 54(5):1304-1313.
52. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, Campbell-Thompson M, Crawford J, Shek EW, Scarpace PJ, Zolotukhin S: Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA (2003) 100(24):14217-14222.
53. Fu Y, Luo N, Klein RL, Garvey WT: Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res (2005) 46(7):1369-1379.
54. Scherer PE: Adiponectin and resistin - adipokines modulating insulin signaling. Molecular Control of Adipogenesis and Obesity, Keystone Symposia, Keystone, CO, USA (2005).
55. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS: Adiponectin acts in the brain to decrease body weight. Nat Med (2004) 10(5):524-529.
56. y/a) obese mice. Diabetes (2003) 52(9):2266-2273.
57. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest (2003) 112(1):91-100.
58. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M et al: Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J Biol Chem (2003) 278(4):2461-2468.
59. Tsao TS, Tomas E, Murrey HE, Hug C, Lee DH, Ruderman NB, Heuser JE, Lodish HF: Role of disulfide bonds in ACRP30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem (2003) 278(50):50810-50817.
60. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K et al: Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology (2002) 143(3):998-1007.
61. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H et al: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 50(9):2094-2099.
62. Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural A et al: Peroxisome proliferator-activated receptor γ (PPAR-γ) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocrine (2004) 26(3):207-214.
63. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, Nomura N, Miyazaki A, Iguchi A: Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care (2003) 26(2):285-289.
64. Inukai K, Watanabe M, Nakashima Y, Takata N, Isoyama A, Sawa T, Kurihara S, Awata T, Katayama S: Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-γ activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2005) 328(2):484-490.
65. Chinetti G, Zawadski C, Fruchart JC, Steels B: Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR. Biochem Biophys Res Commun (2004) 314(1):151-158.
66. Narasimhan ML, Coca MA, Jin J, Yamauchi T, Ito Y, Kadowaki T, Kim KK, Pardo JM, Damsz B, Hasegawa PM, Yuri DJ et al: Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell (2005) 17(2):171-180.